CRISPR Therapeutics AG (LTS:0VRQ) 3-Year Revenue Growth Rate : 735.70% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is CRISPR Therapeutics AG 3-Year Revenue Growth Rate?

CRISPR Therapeutics AG's Revenue per Share for the three months ended in Mar. 2024 was $0.00.

During the past 12 months, CRISPR Therapeutics AG's average Revenue per Share Growth Rate was 166.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 735.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 27.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 10 years, the highest 3-Year average Revenue per Share Growth Rate of CRISPR Therapeutics AG was 735.70% per year. The lowest was -89.40% per year. And the median was 115.25% per year.

Competitive Comparison of CRISPR Therapeutics AG's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, CRISPR Therapeutics AG's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CRISPR Therapeutics AG's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's 3-Year Revenue Growth Rate falls into.

CRISPR Therapeutics AG 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

CRISPR Therapeutics AG (LTS:0VRQ) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

CRISPR Therapeutics AG 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG (LTS:0VRQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

CRSP:USA CRSP:Mexico

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

CRISPR Therapeutics AG (LTS:0VRQ) Headlines

No Headlines